Vinflunine (VFL) has been approved in Europe for second-line treatment of metastatic and
advanced urothelial cancer after failure of platin-containing therapy. Since approval, the …

Objective: The objective of this retrospective study was to investigate the efficacy and safety
of vinflunine monotherapy and the utility of second-line prognostic factors in patients with …

Background Vinflunine is recommended in the European guideline for the treatment of
advanced or metastatic urothelial cell carcinoma (UCC) after failure of platinum-based …

Background Vinflunine is the only chemotherapeutic agent shown to improve survival in
platinum-refractory patients with metastatic transitional cell carcinoma of the urothelium …

Background: A systematic review and meta-analysis of the use of systemic vinflunine (VIN)
in the treatment of urothelial carcinoma (UC) was performed to evaluate its efficacy based on …

Background To retrospectively assess the efficacy and safety of Vinflunine (VFL) under
routine conditions and identify overall survival (OS) prognostic factors. Methods Twenty …

Accounting for 14,000 deaths in the USA last year, research informs us that advanced
bladder cancer is a lethal disease with a median survival that has remained a little over 1 …

BACKGROUND: The activity and safety of vinflunine was evaluated in patients with locally
advanced or metastatic urothelial carcinoma (UC) who developed disease progression …

In 2009, vinflunine was introduced as a second‑line treatment to be used after the failure of
platinum therapy in patients with metastatic urothelial carcinoma (mUC). The present study …

Relapsed urothelial cancer represents an unmet medical need. Vinflunine is a third-
generation antimicrotubuline inhibitor and is currently the only approved drug for second …